Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL OF CLASS III MEDICAL DEVICE REGISTRATION CERTIFICATE FOR PGT-M KIT

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that on April 28, 2026, the Company successfully obtained the national Class III medical device registration certificate for its independently developed "Pre-implantation Genetic Testing Kit for Thalassemia (Semiconductor Sequencing Method)" (PGT-M Kit) (registration certificate No.: Guo Xie Zhu Zhun 20263400858), becoming the first pre-implantation thalassemia testing kit approved for market launch in China. The kit is intended for qualitative detection of genomic DNA from trophectoderm cells of in vitro cultured embryos and from both parents and/or relevant relatives, and uses linkage analysis to determine whether an embryo has inherited parental pathogenic variants, thereby assisting clinicians in selecting appropriate embryos for transfer.

An autosomal recessive genetic haemoglobinopathy caused by defects in the globin genes, thalassemia is one of the most widely distributed and prevalent birth-defect conditions worldwide. It is estimated that approximately 30 million thalassemia gene carriers reside in China, of whom around 300,000 are affected by the severe or intermediate forms; the annual growth rate is about 10%, with particularly high carrier prevalence in regions south of the Yangtze River. For couples who both carry pathogenic variants of the same thalassemia gene, each pregnancy carries a 1/4 risk of producing a child to be affected by severe or intermediate thalassemia.

The approved PGT-M Kit is the first domestically developed PGT-M product in China specifically targeting familial thalassemia genetic prevention, filling a gap in the domestic market for home-grown pre-implantation genetic testing for monogenic disorders. This kit has participated in a localization project under the Chinese mainland's 14th Five-Year Plan key R&D initiative on "Reproductive Health and Women and Children's Health Protection", and can fundamentally prevent transmission of thalassemia genes to the next generation, helping affected families to have healthy infants and reducing the incidence of birth defects.

The Company currently maintains over 50% share of the PGT-compliant market in China; it has established collaborations with approximately 300 hospitals nationwide, co-established over 60 joint laboratories, and secured deep partnerships with more than 80 leading third-generation reproductive centers, forming a comprehensive PGT product portfolio spanning PGT-A, PGT-M and PGT-SR kits. With the approval for market launch of the PGT-M Kit, the Group's product offering is further broadened, which will effectively drive revenue growth in the genetic laboratory business and is expected to become a material growth driver for the Company's future performance, further consolidating the Group's leadership in the Chinese market for third-generation IVF genetic testing kits.

The National Health Commission continues to advance programs to enhance birth-defect prevention and control capacity, and has issued clinical pathways for priority conditions including thalassemia to promote improved medical protection, along with standardized diagnosis and treatment. The successful approval of the PGT-M Kit provides a more precise and efficient pre-conception genetic testing tool for thalassemia control in the Chinese mainland, and is of significant importance to strengthening the China's birth-defect prevention capabilities.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, April 29, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.